Research progress on sensitization mechanism of gemcitabine combined with other drugs in treatment of pancreatic cancer
Pancreatic cancer is a common malignant tumor in the digestive tract. Gemcitabine based drug therapy is still a necessary choice for patients with pancreatic cancer,but drug resistance greatly limits its effectiveness. Gemcitabine combined with other drugs can inhibit the expression and activity of ribonucleotide reductase,up-regulate the expression of deoxycytidine kinase or increase the ratio of deoxycytidine kinase to cytidine deaminase,affect cell cycle,promote DNA damage or inhibit its repair,inhibit NF-κB,PI3K/Akt,STAT,and Nrf2 signal pathway,activate the cell autophagy pathway,and affect epithelial mesenchymal transformation (EMT) to increase the sensitivity of pancreatic cancer cells to gemcitabine. This article reviews the mechanism of gemcitabine combined with other drugs to increase sensitivity,in order to provide reference for its clinical application.
NETL
NSTL
万方数据
